(3S,5S,6R)-3-[(2R,4R,5S)-3-acetamido-5-[(2R,3S,5S)-5-[(2R,4R,5S)-3-acetamido-4-hydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-carboxy-3,4-dihydroxyoxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(2-aminoethoxy)-4,5-dihydroxyoxane-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3S,5S,6R)-3-[(2R,4R,5S)-3-acetamido-5-[(2R,3S,5S)-5-[(2R,4R,5S)-3-acetamido-4-hydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-carboxy-3,4-dihydroxyoxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(2-aminoethoxy)-4,5-dihydroxyoxane-2-carboxylic acid
• 化学式: C₃₁H₅₁N₃O₂₃
• 分子量: 833.7
• InChiKey: XNCGZTPCRAMNEQ-ABBNQAPKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -11.2
• 重原子数：
  57
• 可旋转键数：
  16
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  404
• 氢给体数：
  13
• 氢受体数：
  24

文献信息

• COAGULATION FACTOR VII POLYPEPTIDES
  申请人：Novo Nordisk A/S

  公开号：US20150105321A1

  公开（公告）日：2015-04-16

  The present invention relates to modified coagulation Factor VII polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment.

  本发明涉及改性凝血因子VII多肽，其表现出增强的抗抗凝血酶失活能力和增强的蛋白酶活性。本发明还涉及编码这种多肽的多核苷酸构建物、包含和表达这种多核苷酸的载体和宿主细胞、制药组合物、用途和治疗方法。
• Coagulation Factor IX Conjugates
  申请人：Novo Nordisk A/S

  公开号：US20150225710A1

  公开（公告）日：2015-08-13

  The present invention relates to Factor IX polypeptides conjugated to heparosan (HEP) polymers, methods for the manufacture thereof and uses of such conjugates. The resultant conjugates may be used—for example—in the treatment or prevention of bleeding disorders such as haemophilia B.

  本发明涉及将Factor IX多肽与Heparosan（HEP）聚合物结合的方法，制造方法以及这种结合物的用途。所得到的结合物可以用于治疗或预防出血性疾病，如血友病B。
• Factor VIII Conjugates
  申请人：NOVO NORDISK A/S

  公开号：US20150224203A1

  公开（公告）日：2015-08-13

  The present invention relates to FVIII conjugated to heparosan (HEP) polymers, methods for the manufacture thereof and uses of such conjugates. The resultant conjugates may be used in the treatment or prevention of bleeding disorders such as haemophilia.

  本发明涉及到与肝素硫酸聚合物（HEP）共轭的FVIII，其制造方法以及这种共轭物的用途。得到的共轭物可以用于治疗或预防出血性疾病，例如血友病。
• Factor VII Conjugates
  申请人：NOVO NORDISK A/S

  公开号：US20150225711A1

  公开（公告）日：2015-08-13

  The present invention relates to the conjugation of Factor VII polypeptides with heparosan polymers. The resultant conjugates may be used to deliver Factor VII, for example in the treatment or prevention of bleeding disorder
• US9370583B2
  申请人：——

  公开号：US9370583B2

  公开（公告）日：2016-06-21